Correction to XenoPort Story
May 15 2014 - 9:08AM
Dow Jones News
"XenoPort Reaches Licensing Deal With Reckitt Benckiser"
published at 8:21 a.m. EDT incorrectly said XenoPort is planning a
Phase IIB study of arbaclofen placarbil. Reckitt Benckiser is
planning the study.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Cencora (NYSE:COR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cencora (NYSE:COR)
Historical Stock Chart
From Jul 2023 to Jul 2024